Search - tctmd.com

Displaying 981 - 1000 of 1346

Sort: Relevancy | Date

News Daily News

Studies Explore Impact of Diabetes on Platelet Reactivity in Clopidogrel-Treated PCI Patients

October 10, 2014

News Daily News

Estudios Exploran el Impacto de la Diabetes sobre la Reactividad Plaquetaria en Pacientes PCI a Tratamiento con Clopodogrel

October 10, 2014

News Daily News

CORONOR Registry: Long-term Warfarin Plus Antiplatelet Increases Bleeding in Stable CAD Patients

L.A. McKeown

October 03, 2014

Presentation TCT 2014

Con: Follow the Data and Save the Patient!

Presenter: Adrian P. Banning, Gregg W. Stone

September 16, 2014

Presentation TCT 2014

Pro: Follow the Data - and Save the Money!

Presenter: Adrian P. Banning, Rod H. Stables

September 16, 2014

Presentation TCT 2014

Safety and Effectiveness of Prasugrel vs_ Clopidogrel in the Setting of Bivalirudin vs_ Heparin Use: 30-day Results from TRANSLATE-ACS

Presenter: Timothy Henry

September 16, 2014

Presentation TCT 2014

Heparin versus Bivalirudin in patients undergoing Percutaneous Coronary Intervention

Presenter: Ahmed Rehmani

September 16, 2014

Presentation TCT 2014

TCT 460: Bivalirudin Versus Heparin During Percutaneous Coronary Intervention: A Meta-analysis of Randomized Trials

Presenter: John A. Bittl, Tullio Palmerini, Salvatore Cassese, MD

September 15, 2014

Presentation TCT 2014

TRANSLATE-ACS: A Large-Scale Registry Comparing Patterns of Use and One-Year Outcomes with Prasugrel Versus Clopidogrel in Patients with Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention

Presenter: Stefan K. James, Cindy L. Grines, Tracy Y. Wang

September 15, 2014

Presentation TCT 2014

BRIGHT: A Prospective, Randomized Trial of Bivalirudin Monotherapy Versus Heparin Monotherapy Versus Heparin Plus Tirofiban in Patients with Acute Myocardial Infarction Undergoing Coronary Intervention

Presenter: Roxana Mehran, Harvey D. White, Yaling Han

September 15, 2014

Presentation TCT 2014

Time to Move to 3-6 Months Even in ACS!

Presenter: Marco Valgimigli

September 14, 2014

Presentation TCT 2014

TCT 467: Bivalirudin vs Heparin for Percutaneous Coronary Intervention: An Updated Meta-analysis of Randomized Controlled Trials

Presenter: David J. Moliterno, E. Magnus Ohman, Duane S. Pinto, Michael Lipinski

September 14, 2014

Presentation TCT 2014

The Data Strongly Support Heparin!

Presenter: Rod H. Stables

September 14, 2014

Presentation TCT 2014

The Data Strongly Support Bivalirudin!

Presenter: Gregg W. Stone

September 14, 2014

Presentation TCT 2014

The Data Strongly Support Heparin!

Presenter: Stefanie Schüpke

September 14, 2014

Presentation TCT 2014

The Data Strongly Support Bivalirudin!

Presenter: Roxana Mehran

September 14, 2014

Presentation TCT 2014

Position Statement: Heparin Will Once Again Become the Anticoagulant of Choice for PCI in Stable and Unstable Coronary Syndromes

Presenter: Kishore J. Harjai, Michael S. Lee

September 14, 2014

News Conference News TCT 2014

EUROMAX Substudy: Bivalirudin Noninferior to Heparin Plus GPI for Myocardial Reperfusion

September 14, 2014

Presentation TCT 2014

Role of New Oral Anticoagulants and New ADP Antagonists in ACS Patients

Presenter: Roxana Mehran, Mohamed Sobhy

September 13, 2014

Presentation TCT 2014

Antithrombin Therapy and GP IIb/IIIa Inhibitors in Patients with ACS and in Those Undergoing PCI

Presenter: Frederick Feit, Sripal Bangalore

September 13, 2014

Advertisement

Studies Explore Impact of Diabetes on Platelet Reactivity in Clopidogrel-Treated PCI Patients

Estudios Exploran el Impacto de la Diabetes sobre la Reactividad Plaquetaria en Pacientes PCI a Tratamiento con Clopodogrel

CORONOR Registry: Long-term Warfarin Plus Antiplatelet Increases Bleeding in Stable CAD Patients

Con: Follow the Data and Save the Patient!

Pro: Follow the Data - and Save the Money!

Safety and Effectiveness of Prasugrel vs_ Clopidogrel in the Setting of Bivalirudin vs_ Heparin Use: 30-day Results from TRANSLATE-ACS

Heparin versus Bivalirudin in patients undergoing Percutaneous Coronary Intervention

TCT 460: Bivalirudin Versus Heparin During Percutaneous Coronary Intervention: A Meta-analysis of Randomized Trials

TRANSLATE-ACS: A Large-Scale Registry Comparing Patterns of Use and One-Year Outcomes with Prasugrel Versus Clopidogrel in Patients with Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention

BRIGHT: A Prospective, Randomized Trial of Bivalirudin Monotherapy Versus Heparin Monotherapy Versus Heparin Plus Tirofiban in Patients with Acute Myocardial Infarction Undergoing Coronary Intervention

Time to Move to 3-6 Months Even in ACS!

TCT 467: Bivalirudin vs Heparin for Percutaneous Coronary Intervention: An Updated Meta-analysis of Randomized Controlled Trials

The Data Strongly Support Heparin!

The Data Strongly Support Bivalirudin!

The Data Strongly Support Heparin!

The Data Strongly Support Bivalirudin!

Position Statement: Heparin Will Once Again Become the Anticoagulant of Choice for PCI in Stable and Unstable Coronary Syndromes

EUROMAX Substudy: Bivalirudin Noninferior to Heparin Plus GPI for Myocardial Reperfusion

Role of New Oral Anticoagulants and New ADP Antagonists in ACS Patients

Antithrombin Therapy and GP IIb/IIIa Inhibitors in Patients with ACS and in Those Undergoing PCI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content